Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial sites largely located in major cities, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.
Continue Reading this article here
